Legend Biotech (NASDAQ:LEGN) Stock Price Expected to Rise, HC Wainwright Analyst Says

Legend Biotech (NASDAQ:LEGN) had its price objective upped by HC Wainwright from $73.00 to $75.00 in a report released on Wednesday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.11 EPS.

Several other equities analysts have also weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Legend Biotech in a research note on Monday, December 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $79.09.

Legend Biotech Stock Down 2.2 %

Shares of NASDAQ:LEGN opened at $37.20 on Wednesday. The stock’s 50-day moving average price is $35.68 and its two-hundred day moving average price is $40.97. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. Legend Biotech has a 12-month low of $30.17 and a 12-month high of $69.17. The firm has a market cap of $6.79 billion, a price-to-earnings ratio of -39.16 and a beta of 0.19.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.46. The firm had revenue of $186.50 million for the quarter, compared to analyst estimates of $179.00 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm’s quarterly revenue was up 134.6% on a year-over-year basis. During the same period last year, the company earned ($0.40) EPS. On average, research analysts forecast that Legend Biotech will post -1.31 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lansforsakringar Fondforvaltning AB publ acquired a new position in Legend Biotech during the 4th quarter valued at approximately $914,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Legend Biotech during the 4th quarter valued at approximately $776,000. Polar Asset Management Partners Inc. boosted its position in Legend Biotech by 65.8% during the 4th quarter. Polar Asset Management Partners Inc. now owns 24,638 shares of the company’s stock valued at $802,000 after purchasing an additional 9,779 shares during the period. GF Fund Management CO. LTD. acquired a new position in Legend Biotech during the 4th quarter valued at approximately $56,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Legend Biotech by 36.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,438 shares of the company’s stock valued at $4,440,000 after purchasing an additional 36,181 shares during the period. Institutional investors and hedge funds own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).